|  | | 8200 | Low-LevelLaserTherapy07.00.14i | Medicine (07) | 07.00.14i | 07.00.14 | ff54db2a-d4c9-4bc1-9852-bd476768943a | Low-Level Laser Therapy | Low-Level Laser Therapy | |
|  | | 7909 | Abatacept(Orencia®)forInjectionforIntravenousUse08.00.62r | Pharmacy (08) | 08.00.62r | 08.00.62 | 0cdfa197-861f-4507-8f37-a8d7b9435ffb | Abatacept (Orencia®) for Injection for Intravenous Use | Abatacept (Orencia®) for Injection for Intravenous Use | {"7910": {"Id":7910,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":9995,"PolicyAttachmentPageName":"04494cf2-18a7-4138-a8b8-3c3bcd4092b9"},} |
|  | | 8605 | AblationofLungTumors11.00.16k | Surgery (11) | 11.00.16k | 11.00.16 | 08354f57-a9df-4cdb-8605-e39818199d3a | Ablation of Lung Tumors | Ablation of Lung Tumors | |
|  | | 8259 | Acupuncture12.00.01i | Miscellaneous (12) | 12.00.01i | 12.00.01 | 8d8979e8-6906-43bc-8899-2aca3ffdd751 | Acupuncture | Acupuncture | {"8260": {"Id":8260,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":10302,"PolicyAttachmentPageName":"8bf9e1dc-64be-48d6-930d-0a52ad405e8e"},} |
|  | | 7781 | AcuteCareFacilityInpatientTransfers12.04.04b | Miscellaneous (12) | 12.04.04b | 12.04.04 | 9d5c2f34-6177-4cbe-967c-fc6c80eb5810 | Acute Care Facility Inpatient Transfers | Acute Care Facility Inpatient Transfers | |
|  | | 7519 | ADAMTS13,recombinant-krhn(Adzynma)08.02.21 | Pharmacy (08) | 08.02.21 | 08.02.21 | fd008533-34c4-4ed3-ba7e-e3a4ac663f0f | ADAMTS13, recombinant-krhn (Adzynma) | ADAMTS13, recombinant-krhn (Adzynma) | |
|  | | 7991 | Ado-TrastuzumabEmtansine(Kadcyla®)08.01.11j | Pharmacy (08) | 08.01.11j | 08.01.11 | 1ede2684-4822-4a03-b66b-ed1000fcf81f | Ado-Trastuzumab Emtansine (Kadcyla®) | Ado-Trastuzumab Emtansine (Kadcyla®) | |
|  | | 8346 | Afamitresgeneautoleucel(Tecelra®)08.02.32a | Pharmacy (08) | 08.02.32a | 08.02.32 | 4758c78a-1e05-4951-8f9d-d374b7d2607e | Afamitresgene autoleucel (Tecelra®) | Afamitresgene autoleucel (Tecelra®) | |
|  | | 8347 | Agalsidasebeta(Fabrazyme®)andpegunigalsidasealfa-iwxj(Elfabrio)08.00.69d | Pharmacy (08) | 08.00.69d | 08.00.69 | 6ae71c67-4905-4441-9792-103799004bce | Agalsidase beta (Fabrazyme®) and pegunigalsidase alfa-iwxj (Elfabrio) | Agalsidase beta (Fabrazyme®) and pegunigalsidase alfa-iwxj (Elfabrio) | |
|  | | 7879 | AirAmbulanceServices12.04.03d | Miscellaneous (12) | 12.04.03d | 12.04.03 | e1ea2509-f318-4875-b48b-fc16bb7c5517 | Air Ambulance Services | Air Ambulance Services | |
|  | | 7838 | Alemtuzumab(Lemtrada®)08.01.22e | Pharmacy (08) | 08.01.22e | 08.01.22 | f38164fa-91fd-4e3b-a62a-4a24cdfa2a60 | Alemtuzumab (Lemtrada®) | Alemtuzumab (Lemtrada®) | |
|  | | 8473 | Alglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®),Cipaglucosidasealfa-atga(Pombiliti™)08.00.72l | Pharmacy (08) | 08.00.72l | 08.00.72 | f78ee04f-b763-47ec-9b46-8e442c19b589 | Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ ) | Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ ) | |
|  | | 8430 | AllergyImmunotherapy07.00.21k | Medicine (07) | 07.00.21k | 07.00.21 | 53d13a94-5654-4cfd-b1c5-4a656717e2f1 | Allergy Immunotherapy | Allergy Immunotherapy | |
|  | | 8601 | AllogeneicProcessedThymusTissue-agdc(Rethymic®)08.01.88b | Pharmacy (08) | 08.01.88b | 08.01.88 | 209dee3a-83a5-45ce-9f57-83defef9b35e | Allogeneic Processed Thymus Tissue-agdc (Rethymic®) | Allogeneic Processed Thymus Tissue-agdc (Rethymic®) | |
|  | | 8338 | AlloMap™MolecularExpressionTestingforHeartTransplantRejection(AmeriHealthAdministrators)06.02.29g | Pathology and Laboratory (06) | 06.02.29g | 06.02.29 | c638673c-6433-4d3e-85a2-235799915fdd | AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (AmeriHealth Administrators) | AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (AmeriHealth Administrators) | |
|  | | 8525 | Alpha-1AntitrypsinTherapy(e.g.,Prolastin-C®,AralastNP®,Glassia®,Zemaira®)08.00.91f | Pharmacy (08) | 08.00.91f | 08.00.91 | 26c797a4-e6a5-4143-8587-6242d11c6ad4 | Alpha-1 Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®) | Alpha-1 Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®) | |
|  | | 8451 | AmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)Devices07.02.09k | Medicine (07) | 07.02.09k | 07.02.09 | f02dd513-baba-4592-8efe-f63835d1ab20 | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | |
|  | | 8600 | AmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)Monitoring07.02.21r | Medicine (07) | 07.02.21r | 07.02.21 | d6e22cf1-f860-4ba4-bd1f-653d6f1d17e0 | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | |
|  | | 8504 | Amivantamab-vmjw(Rybrevant®)andAmivantamabandhyaluronidase-lpuj(RybrevantFaspro™)08.01.90c | Pharmacy (08) | 08.01.90c | 08.01.90 | 4be0de04-e277-4a85-ae2d-b2deb35e8f21 | Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™) | Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™) | |
|  | | 8316 | AnesthesiaServicesforEpidural,ParavertebralFacetandSacroiliacJointInjectionsforSpinalJointManagement01.00.12d | Anesthesia (01) | 01.00.12d | 01.00.12 | fa80afe7-2a2d-4bef-8751-39ae4b420c8f | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | {"8317": {"Id":8317,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":10365,"PolicyAttachmentPageName":"68840056-6ccf-4e86-9e09-4fbc9b1b12a4"},} |
|  | | 8533 | Anifrolumab-fnia(Saphnelo®)08.01.82c | Pharmacy (08) | 08.01.82c | 08.01.82 | bb14ca28-1d81-4987-92f9-a494abd49a2b | Anifrolumab-fnia (Saphnelo®) | Anifrolumab-fnia (Saphnelo®) | |
|  | | 7778 | Ankle-Foot/Knee-Ankle-FootOrthoses05.00.39v | DME (05) | 05.00.39v | 05.00.39 | 966bd452-6338-41a9-92af-732491b02dc4 | Ankle-Foot/Knee-Ankle-Foot Orthoses | Ankle-Foot/Knee-Ankle-Foot Orthoses | {"7779": {"Id":7779,"MPAttachmentLetter":"A","Title":"HCPCS Codes","MPPolicyAttachmentInternalSourceId":10050,"PolicyAttachmentPageName":"a9a20411-76a0-4e64-939d-66d5b2da8b70"},} |
|  | | 8370 | ApheresisTherapy06.03.04p | Pathology and Laboratory (06) | 06.03.04p | 06.03.04 | 165b3086-cdfc-4bf5-b4db-0692080dd2f9 | Apheresis Therapy | Apheresis Therapy | |
|  | | 8082 | Apos®biomechanicalshoesystem05.00.84 | DME (05) | 05.00.84 | 05.00.84 | 67425cc3-07be-4535-8f98-aa782aed6207 | Apos® biomechanical shoe system | Apos® biomechanical shoe system | |
|  | | 8319 | ApplicationandRemovalofTattoos11.08.05g | Surgery (11) | 11.08.05g | 11.08.05 | 2dbac49d-cffb-48cb-ae51-d478c1803762 | Application and Removal of Tattoos | Application and Removal of Tattoos | |
|  | | 8121 | AppliedBehaviorAnalysis(ABA)fortheTreatmentofAutismSpectrumDisorder(ASD)14.00.03b | Behavioral Health (14) | 14.00.03b | 14.00.03 | df5a4d4b-0bc7-4458-844b-0a350f6cb8b0 | Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD) | Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD) | |
|  | | 7785 | AqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucoma11.05.16m | Surgery (11) | 11.05.16m | 11.05.16 | 27d52305-5f49-4a7a-9192-b9f44905dbd6 | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | {"7786": {"Id":7786,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":9964,"PolicyAttachmentPageName":"15735e06-1e8c-4776-aee0-d7ce2e3e06a9"},} |
|  | | 7479 | ArtificialIntervertebralCervicalDiscInsertion(AmeriHealthAdministrators)11.14.19p | Surgery (11) | 11.14.19p | 11.14.19 | 35245b24-5bf6-4802-9442-902d406c9e67 | Artificial Intervertebral Cervical Disc Insertion (AmeriHealth Administrators) | Artificial Intervertebral Cervical Disc Insertion (AmeriHealth Administrators) | |
|  | | 8541 | AsparaginaseErwiniaChrysanthemi(recombinant)-rywn(Rylaze®)08.01.35k | Pharmacy (08) | 08.01.35k | 08.01.35 | c32128a7-4f5b-4e57-975b-151084683596 | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®) | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®) | |
|  | | 7261 | AssaysofGeneticExpressioninTumorTissueforBreastCancerPrognosis(AmeriHealthAdministrators)06.02.27p | Pathology and Laboratory (06) | 06.02.27p | 06.02.27 | 56cacc55-1d7c-498d-927b-8a69cac0aca7 | Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (AmeriHealth Administrators) | Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (AmeriHealth Administrators) | |
|  | | 6631 | AssistedReproductiveTechnologyforInfertilityandOocyteCryopreservation07.10.06j | Medicine (07) | 07.10.06j | 07.10.06 | 6f3e894a-05bc-4cd3-bdef-f6cbc845ef41 | Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation | Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation | |
|  | | 7701 | Atezolizumab(Tecentriq®)andAtezolizumabwithHyaluronidase-tqjs(TecentriqHybreza™)08.01.69f | Pharmacy (08) | 08.01.69f | 08.01.69 | 992f3189-6d0f-4926-9bac-58206601cacc | Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™) | Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™) | |
|  | | 7534 | Atidarsageneautotemcel(Lenmeldy)08.02.24 | Pharmacy (08) | 08.02.24 | 08.02.24 | 2b1b1765-a231-4988-a244-9ccb24ccbfcf | Atidarsagene autotemcel (Lenmeldy) | Atidarsagene autotemcel (Lenmeldy) | |
|  | | 8567 | AuricularProstheses05.00.82 | DME (05) | 05.00.82 | 05.00.82 | 67c56876-fd07-4da6-8475-885f05f5d615 | Auricular Prostheses | Auricular Prostheses | |
|  | | 8597 | AutologousChondrocyteImplantation(ACI)andOtherCell-basedTreatmentsofFocalArticularCartilageLesions(AmerihealthAdministrators)11.14.06j | Surgery (11) | 11.14.06j | 11.14.06 | 2df99a15-e872-4a2a-a4a5-442c6c4fa4da | Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Amerihealth Administrators) | Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Amerihealth Administrators) | |
|  | | 7358 | AutomaticExternalCardioverterDefibrillators(WearableandNonwearable)05.00.29o | DME (05) | 05.00.29o | 05.00.29 | b070d704-cac3-4d95-a688-af44923ad4c7 | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | {"7359": {"Id":7359,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":9496,"PolicyAttachmentPageName":"b88cf6f5-b2af-4a66-ba3e-b679772bdb77"},"7360": {"Id":7360,"MPAttachmentLetter":"A","Title":"ICD-10 Codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":9497,"PolicyAttachmentPageName":"af7d0a09-cd8a-4014-8ebb-fc602687e3ce"},} |
|  | | 8335 | AutonomicNervousSystemTesting07.03.23h | Medicine (07) | 07.03.23h | 07.03.23 | 5bc6bc6c-9e83-4835-b48d-e28ef61d1f82 | Autonomic Nervous System Testing | Autonomic Nervous System Testing | |
|  | | 8113 | Avelumab(Bavencio®)08.01.64e | Pharmacy (08) | 08.01.64e | 08.01.64 | 2424724c-1f94-42dd-ad72-c1bf210b7b93 | Avelumab (Bavencio®) | Avelumab (Bavencio®) | |
|  | | 8435 | Axatilimab-csfr(Niktimvo™)forIntravenousUse08.02.34 | Pharmacy (08) | 08.02.34 | 08.02.34 | 73be2894-abe5-401d-8e57-3269b6d8e68b | Axatilimab-csfr (Niktimvo™) for Intravenous Use | Axatilimab-csfr (Niktimvo™) for Intravenous Use | |
|  | | 7335 | BalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitisorRecurrentAcuteRhinosinusitis11.16.06k | Surgery (11) | 11.16.06k | 11.16.06 | 9999fe02-c4cf-48bc-82cc-4ce3045f0ad8 | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis | |
|  | | 8088 | BariatricSurgery11.03.02x | Surgery (11) | 11.03.02x | 11.03.02 | 446fd623-e591-4f59-8c9d-70741e333774 | Bariatric Surgery | Bariatric Surgery | {"8089": {"Id":8089,"MPAttachmentLetter":"B","Title":"Tanner Staging System Criteria for Adolescents","MPPolicyAttachmentInternalSourceId":10120,"PolicyAttachmentPageName":"9fcd9d05-43a3-4c43-a472-6e465bfeb378"},"8090": {"Id":8090,"MPAttachmentLetter":"A","Title":"Body Mass Index (BMI) Charts","MPPolicyAttachmentInternalSourceId":10121,"PolicyAttachmentPageName":"1f1f186c-15dd-4394-9733-9b4fb88b2036"},} |
|  | | 8517 | Belantamabmafodotin-blmf(Blenrep)08.02.53 | Pharmacy (08) | 08.02.53 | 08.02.53 | fe2c5777-01fe-4e36-b4df-0eafeab95c46 | Belantamab mafodotin-blmf (Blenrep) | Belantamab mafodotin-blmf (Blenrep) | |
|  | | 7531 | Belimumab(Benlysta®)forIntravenousUse08.00.99e | Pharmacy (08) | 08.00.99e | 08.00.99 | b2ee0b0f-5fe4-4e5e-8728-9b6ea3d508dd | Belimumab (Benlysta®) for Intravenous Use | Belimumab (Benlysta®) for Intravenous Use | |
|  | | 8095 | BeremageneGeperpavec(Vyjuvek™)08.02.10b | Pharmacy (08) | 08.02.10b | 08.02.10 | e4dc72b0-021c-45ca-8da8-946b4b5692fc | Beremagene Geperpavec (Vyjuvek™) | Beremagene Geperpavec (Vyjuvek™) | |
|  | | 7518 | BetibeglogeneAutotemcel[Beti-Cel(ZYNTEGLO®)]08.01.89a | Pharmacy (08) | 08.01.89a | 08.01.89 | fc30b8b9-db7c-4141-a327-57e532d8259c | Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)] | Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)] | |
|  | | 8493 | Bevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUse08.00.66x | Pharmacy (08) | 08.00.66x | 08.00.66 | 460ade68-9fc2-4458-9c8d-6cb709778838 | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | {"8494": {"Id":8494,"MPAttachmentLetter":"A","Title":"ICD 10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":10203,"PolicyAttachmentPageName":"f4810066-c22a-4d76-9e03-0beab38cdae8"},} |
|  | | 8233 | BillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampus00.10.39r | Administrative (00) | 00.10.39r | 00.10.39 | 9c766e44-e195-4f55-8f8a-df1e202967cc | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | {"8234": {"Id":8234,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus","MPPolicyAttachmentInternalSourceId":10318,"PolicyAttachmentPageName":"7100a278-181d-40b1-88e4-0cf1d3e576d0"},} |
|  | | 6405 | BillingRequirementsforMultipleBirthsforProfessionalProviders00.10.38a | Administrative (00) | 00.10.38a | 00.10.38 | 9be43eff-6b64-4e0b-a426-ef73f2537ec3 | Billing Requirements for Multiple Births for Professional Providers | Billing Requirements for Multiple Births for Professional Providers | {"6406": {"Id":6406,"MPAttachmentLetter":"C","Title":"CODING SCENARIOS FOR REPORTING HIGH-ORDER MULTIPLE (TRIPLETS, QUADRUPLETS, ETC) BIRTHS WHEN ROUTINE OBSTETRIC (GLOBAL MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":8677,"PolicyAttachmentPageName":"8f6b9a74-008f-4e82-8be7-60a9d2b4131a"},"6407": {"Id":6407,"MPAttachmentLetter":"A","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ROUTINE OBSTETRIC (GLOBALE MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":8678,"PolicyAttachmentPageName":"b5c1c52a-6755-40e1-89ab-106d03f7d9d6"},"6408": {"Id":6408,"MPAttachmentLetter":"D","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF HIGH-ORDER MULTIPLES WHEN ANTEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":8679,"PolicyAttachmentPageName":"5ae8f316-7805-4e4c-ac92-1e147d896d76"},"6409": {"Id":6409,"MPAttachmentLetter":"B","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ANETEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":8680,"PolicyAttachmentPageName":"1aace5b3-ccc4-4d23-9916-fd982ce3e6ab"},} |
|  | | 8422 | BiofeedbackTherapy07.00.01n | Medicine (07) | 07.00.01n | 07.00.01 | 3d434731-e65e-42c5-8464-72950cf4e61f | Biofeedback Therapy | Biofeedback Therapy | |
|  | | 8006 | BioimpedancefortheDetectionofLymphedema07.06.03c | Medicine (07) | 07.06.03c | 07.06.03 | 53dd50f9-76e1-4658-9cb7-47d83a8f3a09 | Bioimpedance for the Detection of Lymphedema | Bioimpedance for the Detection of Lymphedema | |
|  | | 7944 | Blinatumomab(Blincyto®)08.01.21h | Pharmacy (08) | 08.01.21h | 08.01.21 | 7177f741-41cb-4ce0-851b-6c9601b97a5c | Blinatumomab (Blincyto®) | Blinatumomab (Blincyto®) | |
|  | | 8569 | Bone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAids11.01.06j | Surgery (11) | 11.01.06j | 11.01.06 | 3fd23412-a86e-48d8-bfd5-0dc5d2919e14 | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | |
|  | | 8320 | BoneMineralDensity(BMD)Testing09.00.04o | Radiology (09) | 09.00.04o | 09.00.04 | 76fd8a04-7dba-4a01-8f7c-c8b036be1fa3 | Bone Mineral Density (BMD) Testing | Bone Mineral Density (BMD) Testing | |
|  | | 8016 | BotulinumToxinAgents08.00.26ae | Pharmacy (08) | 08.00.26ae | 08.00.26 | cfa61371-54dc-46c2-8906-306bcd492f8c | Botulinum Toxin Agents | Botulinum Toxin Agents | {"8017": {"Id":8017,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":9954,"PolicyAttachmentPageName":"dbc81970-0297-44d2-8050-066edb615a5c"},} |
|  | | 8349 | BrachytherapyandAcceleratedWholeBreastIrradiationusingThree-DimensionalConformationRadiationTherapy(AmeriHealthAdministrators)09.00.10aa | Radiology (09) | 09.00.10aa | 09.00.10 | c0375b6c-ad1f-4605-8f73-e08805253165 | Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy (AmeriHealth Administrators) | Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy (AmeriHealth Administrators) | |
|  | | 7745 | BreastPumps05.00.76i | DME (05) | 05.00.76i | 05.00.76 | e70095f6-c867-4c3b-9f96-707c3d28eb89 | Breast Pumps | Breast Pumps | |
|  | | 7949 | BrentuximabVedotin(Adcetris®)08.01.13l | Pharmacy (08) | 08.01.13l | 08.01.13 | 1009c2d5-c204-493e-add9-09b73e59a058 | Brentuximab Vedotin (Adcetris®) | Brentuximab Vedotin (Adcetris®) | |
|  | | 7245 | BronchialValves11.16.09 | Surgery (11) | 11.16.09 | 11.16.09 | 74655048-5c3b-4911-803c-fc91117b568f | Bronchial Valves | Bronchial Valves | |
|  | | 8241 | BundledProcedureCodes00.01.52z | Administrative (00) | 00.01.52z | 00.01.52 | 5c7664e8-beec-499d-bb46-36274a82dfe6 | Bundled Procedure Codes | Bundled Procedure Codes | {"8242": {"Id":8242,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":10320,"PolicyAttachmentPageName":"0c7dcad9-4ce9-4615-a629-282b7d8b98e8"},"8243": {"Id":8243,"MPAttachmentLetter":"A","Title":"Always Bundled and Bundled Procedures/Services (MPFSDB Indicators B and T)","MPPolicyAttachmentInternalSourceId":10321,"PolicyAttachmentPageName":"d0eb0a19-5173-468a-afc3-0eccfa38f606"},"8244": {"Id":8244,"MPAttachmentLetter":"D","Title":"Procedures/Services Not Eligible for Separate Reimbursement when reported with another specific Procedure/Service","MPPolicyAttachmentInternalSourceId":10322,"PolicyAttachmentPageName":"c5836cc1-d032-4714-baf5-5d9d72a65fbf"},"8245": {"Id":8245,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":10323,"PolicyAttachmentPageName":"5c47117c-27b4-4693-aa60-f5c64c95a380"},} |
|  | | 7522 | Burosumab-twza(Crysvita®)08.01.49b | Pharmacy (08) | 08.01.49b | 08.01.49 | 90bde7e8-8725-49ce-b0b6-0d9746fc6827 | Burosumab-twza (Crysvita®) | Burosumab-twza (Crysvita®) | |
|  | | 7510 | Canakinumab(Ilaris®)08.01.51c | Pharmacy (08) | 08.01.51c | 08.01.51 | f256b980-3aff-428f-bc76-77eb472ed635 | Canakinumab (Ilaris®) | Canakinumab (Ilaris®) | {"7511": {"Id":7511,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9689,"PolicyAttachmentPageName":"afa88eed-46ec-4c67-a37f-4e048ec24c30"},} |
|  | | 8497 | CardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)Programs10.01.01r | Rehabilitation Services (10) | 10.01.01r | 10.01.01 | 491ed4ee-c053-45a5-b431-3c73f00c7eac | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | {"8498": {"Id":8498,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":10308,"PolicyAttachmentPageName":"67b07c41-6e9f-4a4e-a319-8aeff0cef12e"},} |
|  | | 8239 | CareManagementandCarePlanningServices00.01.59p | Administrative (00) | 00.01.59p | 00.01.59 | 3b542224-8db8-4cad-84ea-ee0cb5482fa6 | Care Management and Care Planning Services | Care Management and Care Planning Services | |
|  | | 8004 | Carfilzomib(Kyprolis®)08.01.05m | Pharmacy (08) | 08.01.05m | 08.01.05 | b6aef6df-ce54-40c9-8e78-94170c6dc59f | Carfilzomib (Kyprolis®) | Carfilzomib (Kyprolis®) | |
|  | | 8542 | Casgevy™(exagamglogeneautotemcel)08.02.14a | Pharmacy (08) | 08.02.14a | 08.02.14 | 6485c996-b386-4a16-8a4d-f7ce3beb8cae | Casgevy™ (exagamglogene autotemcel) | Casgevy™ (exagamglogene autotemcel) | |
|  | | 6738 | CastandSplintApplicationsandAssociatedSupplies00.10.15d | Administrative (00) | 00.10.15d | 00.10.15 | ff41fdec-319e-4608-be2d-eee15f3bec86 | Cast and Splint Applications and Associated Supplies | Cast and Splint Applications and Associated Supplies | {"6739": {"Id":6739,"MPAttachmentLetter":"A","Title":"Procedure Codes Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":8996,"PolicyAttachmentPageName":"e57f2559-9175-4c80-b8ea-259381682441"},} |
|  | | 8575 | CataractSurgery11.01.07g | Surgery (11) | 11.01.07g | 11.01.07 | 0bc270da-8255-40f5-a455-696f7d2724da | Cataract Surgery | Cataract Surgery | {"8576": {"Id":8576,"MPAttachmentLetter":"A","Title":"ICD 10 codes for Cataract Surgery","MPPolicyAttachmentInternalSourceId":10686,"PolicyAttachmentPageName":"91ef7399-cb9d-47c1-8103-840fdd3498f4"},} |
|  | | 8614 | CatheterAblationofCardiacArrhythmias11.02.06r | Surgery (11) | 11.02.06r | 11.02.06 | c9a12f9d-ad89-45d1-96c7-86a63f28a068 | Catheter Ablation of Cardiac Arrhythmias | Catheter Ablation of Cardiac Arrhythmias | |
|  | | 8141 | Cemiplimab-rwlc(Libtayo®)08.01.66e | Pharmacy (08) | 08.01.66e | 08.01.66 | 11d7da82-48d4-4e14-8cc6-7c28d229e130 | Cemiplimab-rwlc (Libtayo®) | Cemiplimab-rwlc (Libtayo®) | |
|  | | 8084 | Cerliponasealfa(Brineura®)08.01.39d | Pharmacy (08) | 08.01.39d | 08.01.39 | 90b30eda-a568-415f-bb16-b6b07bb92be1 | Cerliponase alfa (Brineura®) | Cerliponase alfa (Brineura®) | {"8085": {"Id":8085,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for Cerliponase alfa (Brineura®)","MPPolicyAttachmentInternalSourceId":10163,"PolicyAttachmentPageName":"6ba2a414-3aa7-4d52-8180-cb44354bd4c1"},} |
|  | | 8083 | CervicalTractionDevicesforIn-homeUse05.00.61h | DME (05) | 05.00.61h | 05.00.61 | b9ddf003-4f8f-42e7-9fc6-76de1f37b76d | Cervical Traction Devices for In-home Use | Cervical Traction Devices for In-home Use | |
|  | | 7954 | Cetuximab(Erbitux®)08.00.67o | Pharmacy (08) | 08.00.67o | 08.00.67 | e1ea1dc2-be97-47c4-82b3-2c44d2cbd6fc | Cetuximab (Erbitux®) | Cetuximab (Erbitux®) | {"7955": {"Id":7955,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":9909,"PolicyAttachmentPageName":"83817ed0-6e11-4d2e-af6f-cbc52c32c165"},"7956": {"Id":7956,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":9910,"PolicyAttachmentPageName":"1409a241-43f7-4201-a484-e1757f6b915e"},} |
|  | | 8336 | ChemicalPeels11.08.08h | Surgery (11) | 11.08.08h | 11.08.08 | 12d32814-2f47-4360-958d-2ff7f760c0bc | Chemical Peels | Chemical Peels | |
|  | | 8294 | ChimericAntigenReceptor(CART)Therapy:YescartaTecartus,Breyanzi,KymriahandAucatzyl08.01.43q | Pharmacy (08) | 08.01.43q | 08.01.43 | ff6511be-0057-4580-b617-6ff18dd4500f | Chimeric Antigen Receptor (CART) Therapy: Yescarta Tecartus, Breyanzi, Kymriah and Aucatzyl | Chimeric Antigen Receptor (CART) Therapy: Yescarta Tecartus, Breyanzi, Kymriah and Aucatzyl | |
|  | | 8293 | ChimericAntigenReceptorTherapy(CART):Carvykti®&Abecma®08.02.50 | Pharmacy (08) | 08.02.50 | 08.02.50 | 86386249-6b42-4c68-85e8-8761f7cfefd6 | Chimeric Antigen Receptor Therapy (CART): Carvykti® & Abecma® | Chimeric Antigen Receptor Therapy (CART): Carvykti® & Abecma® | |
|  | | 7689 | ChiropracticSpinalandExtraspinalManipulationTherapy10.02.02k | Rehabilitation Services (10) | 10.02.02k | 10.02.02 | a61acc7b-d9b3-46f0-a7bc-ad7ac57c0075 | Chiropractic Spinal and Extraspinal Manipulation Therapy | Chiropractic Spinal and Extraspinal Manipulation Therapy | |
|  | | 8203 | CoagulationFactors08.00.92ak | Pharmacy (08) | 08.00.92ak | 08.00.92 | bd646084-b825-424c-893e-93c594321e15 | Coagulation Factors | Coagulation Factors | |
|  | | 8105 | Cobalamin(VitaminB12),FolicAcid,andHomocysteineTesting06.02.54d | Pathology and Laboratory (06) | 06.02.54d | 06.02.54 | 53adf5d8-86bb-4c20-9ace-bfa03628c82e | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | {"8106": {"Id":8106,"MPAttachmentLetter":"A","Title":"MEDICALLY NECESSARY ICD 10 CODES FOR COBALAMIN (VITAMIN B12) AND/OR FOLIC ACID TESTING (CPT CODES 82607, 82608, 82746, AND 82747)","MPPolicyAttachmentInternalSourceId":10212,"PolicyAttachmentPageName":"ec2c2d38-1ed4-491f-a1c8-f55d1a5b7892"},} |
|  | | 8577 | CochlearImplantation11.01.02s | Surgery (11) | 11.01.02s | 11.01.02 | ac5abb27-a226-48f7-9ab1-27b3d900c237 | Cochlear Implantation | Cochlear Implantation | |
|  | | 7529 | Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo®)08.01.71 | Pharmacy (08) | 08.01.71 | 08.01.71 | 757a5c90-a2ba-46a4-8874-38c9ccf90021 | Collagenase clostridium histolyticum (Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®) | Collagenase clostridium histolyticum (Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®) | |
|  | | 7573 | ColorectalCancerScreening11.03.12v | Surgery (11) | 11.03.12v | 11.03.12 | 7129422f-5e96-42a8-bca2-bbfca91f1053 | Colorectal Cancer Screening | Colorectal Cancer Screening | |
|  | | 6411 | ComplementaryandIntegrativeHealthServices12.00.03h | Miscellaneous (12) | 12.00.03h | 12.00.03 | ba170083-35f9-4f1e-9e58-e68b05aa307a | Complementary and Integrative Health Services | Complementary and Integrative Health Services | |
|  | | 7681 | CompositeTissueAllotransplantationoftheHand(s)andFace11.14.30 | Surgery (11) | 11.14.30 | 11.14.30 | ac863e9b-e227-4276-a9bc-1969996c53ab | Composite Tissue Allotransplantation of the Hand(s) and Face | Composite Tissue Allotransplantation of the Hand(s) and Face | |
|  | | 8400 | CompressionGarments05.00.37k | DME (05) | 05.00.37k | 05.00.37 | a5238b05-8582-4e67-9f71-859028737a5b | Compression Garments | Compression Garments | |
|  | | 7959 | Computer-AidedDetection(CAD)SystemforUsewithChestRadiographs09.00.42d | Radiology (09) | 09.00.42d | 09.00.42 | b1fa1dff-ec77-46cc-82ba-6cbc54778492 | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | |
|  | | 8311 | Computer-assistedMusculoskeletalSurgicalNavigationalOrthopedicProcedure11.14.17e | Surgery (11) | 11.14.17e | 11.14.17 | 11e14a76-9399-4836-894b-2e02f5997046 | Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | |
|  | | 8070 | ContactLensesfortheTreatmentofPersistent(Corneal)EpithelialDefects07.13.11k | Medicine (07) | 07.13.11k | 07.13.11 | dca4af06-9e87-4c02-85b8-c4538b873975 | Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects | Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects | {"8071": {"Id":8071,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":10160,"PolicyAttachmentPageName":"aed30e55-83dc-4747-9f3c-fa881b5f4fab"},} |
|  | | 7259 | ContrastAgentsUsedinConjunctionwithEchocardiography09.00.11e | Radiology (09) | 09.00.11e | 09.00.11 | c5fd2062-89b8-4c22-a99b-47e4398d8af6 | Contrast Agents Used in Conjunction with Echocardiography | Contrast Agents Used in Conjunction with Echocardiography | |
|  | | 7859 | CornealPachymetryUsingUltrasound07.13.07m | Medicine (07) | 07.13.07m | 07.13.07 | 4db2bfde-0860-4406-bcd3-e3dabdf21d02 | Corneal Pachymetry Using Ultrasound | Corneal Pachymetry Using Ultrasound | {"7860": {"Id":7860,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":9933,"PolicyAttachmentPageName":"f7b9d42c-b23a-47bb-a26c-a889cde6af69"},} |
|  | | 7803 | CoronaryArteryCalcium(CAC)TestingUsingComputedTomography(AmeriHealthAdministrators)09.00.58a | Radiology (09) | 09.00.58a | 09.00.58 | 534ecc67-d1e0-45be-b1ca-a5d9b61f83de | Coronary Artery Calcium (CAC) Testing Using Computed Tomography (AmeriHealth Administrators) | Coronary Artery Calcium (CAC) Testing Using Computed Tomography (AmeriHealth Administrators) | |
|  | | 8590 | Cosibelimab-ipdl(Unloxcyt™)08.02.40a | Pharmacy (08) | 08.02.40a | 08.02.40 | a8618648-4fd5-4cd1-b405-1d0ce673ab07 | Cosibelimab-ipdl (Unloxcyt™) | Cosibelimab-ipdl (Unloxcyt™) | |
|  | | 7171 | CosmeticProcedures12.01.03b | Miscellaneous (12) | 12.01.03b | 12.01.03 | 1b0c4dbc-22e1-4cf2-a8bd-43a74b3675fb | Cosmetic Procedures | Cosmetic Procedures | |
|  | | 8254 | CoverageofAnticancerPrescriptionOralandInjectableDrugsandBiologicsandSupportiveAgents08.01.08v | Pharmacy (08) | 08.01.08v | 08.01.08 | 901403c5-1f07-40cf-8a9b-91b77219cd04 | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | {} |
|  | | 6936 | CoverageofMedicalDevices05.00.04e | DME (05) | 05.00.04e | 05.00.04 | 21580a78-eec4-4b84-a973-1315467a0db9 | Coverage of Medical Devices | Coverage of Medical Devices | |
|  | | 8091 | CranialElectrotherapyStimulation05.00.80d | DME (05) | 05.00.80d | 05.00.80 | d49f3a0d-b1b8-4bfc-a38f-820b6574df5e | Cranial Electrotherapy Stimulation | Cranial Electrotherapy Stimulation | |
|  | | 8568 | CranialRemoldingOrthoses(Helmets)05.00.25k | DME (05) | 05.00.25k | 05.00.25 | 2a1d0d80-f17d-466f-8df1-4a5da9d707b3 | Cranial Remolding Orthoses (Helmets) | Cranial Remolding Orthoses (Helmets) | |
|  | | 7666 | crizanlizumab-tmca(Adakveo®)08.00.04b | Pharmacy (08) | 08.00.04b | 08.00.04 | 218e477c-e785-44d2-b69d-cce973f7e4c8 | crizanlizumab-tmca (Adakveo®) | crizanlizumab-tmca (Adakveo®) | |
|  | | 7491 | Crovalimab-akkz(Piasky)08.02.31 | Pharmacy (08) | 08.02.31 | 08.02.31 | 1279e64b-5553-4dd7-aba9-1b5050638555 | Crovalimab-akkz (Piasky) | Crovalimab-akkz (Piasky) | |
|  | | 8263 | CryosurgicalAblationoftheProstateGland11.11.03d | Surgery (11) | 11.11.03d | 11.11.03 | 8bb9f7de-f753-4689-a82b-7889d45672cc | Cryosurgical Ablation of the Prostate Gland | Cryosurgical Ablation of the Prostate Gland | |
|  | | 7737 | Daratumumab(Darzalex®),DaratumumabandHyaluronidase-fihj(DarzalexFaspro®)08.01.29m | Pharmacy (08) | 08.01.29m | 08.01.29 | 4cdc8ed3-6af8-4e8f-8cb6-e5420b00b644 | Daratumumab (Darzalex®), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro®) | Daratumumab (Darzalex®), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro®) | |